Accessibility Menu
RenovoRx logo

RenovoRx

(NASDAQ) RNXT

Current Price$0.87
Market Cap$38.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-88%
5 YearN/A
1 Year-33%
1 Month-3%
RenovoRx last closing stock price
MetricPriceDate
Last closeUSD 0.872026-07-17
RenovoRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.97%USD 0.932026-07-10
1 month-2.85%USD 0.892026-06-17
3 month-13.47%USD 1.002026-04-17
Year to date+3%USD 0.842025-12-31
1 year-33.44%USD 1.302025-07-17
3 year-58.6%USD 2.092023-07-18
Since inception-88.08%USD 7.262021-08-26

RenovoRx Financials at a Glance

Market Cap

$38.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.49M

Net Income (TTM)

-$12.27M

EPS (TTM)

-$0.33

P/E Ratio

-2.61

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.87

Volume

112,223

Open

$0.86

Previous Close

$0.87

Daily Range

$0.85 - $0.92

52-Week Range

$0.70 - $1.45

Estimated Earnings Date

Aug 13, 2026

RNXT News

Foolcom-Featured.png

RenovoRx Revenue Jumps 28 Percent in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RenovoRx

RenovoRx develops medical devices and therapies for cancer treatment. Its products help doctors deliver chemotherapy directly to tumors. This approach aims to reduce side effects for patients with hard-to-treat cancers.

Gadgets and Gizmos: What RenovoRx Sells

  • RenovoCath device (100% of revenue): A medical tool that delivers chemotherapy directly to tumors, mainly used by U.S. cancer centers.
  • RenovoGem therapy: An experimental treatment combining a drug and device for targeted chemotherapy in pancreatic cancer, currently in clinical trials.
  • TAMP platform: A patented system for delivering drugs through blood vessels to solid tumors, aiming for higher local drug concentration.

Growth Spurts and Strategic Moves

  • Launched RenovoCath as a standalone device in December 2024.
  • Expanded to 12 U.S. cancer centers by February 2026, with 21 more evaluating.
  • Formed a Medical Advisory Board in February 2026 to guide clinical and market strategy.
  • Raised $10 million in March 2026 through a private placement to support operations.

Why RenovoRx Is a Bit Different

RenovoRx focuses on targeted drug delivery, aiming to limit side effects by sending chemotherapy straight to tumors. Its patented technology and FDA-cleared device support a niche approach in cancer care. The company relies on a lean sales model, targeting high-volume treatment centers directly.

Five Things You Need to Know

  • Revenue was $1.1 million in FY 2025, up 2,512% from FY 2024.
  • Gross margin reached 70.9% in FY 2025, reflecting device-focused sales.
  • Net loss was $11.2 million in FY 2025, up 27% from FY 2024.
  • Cash and equivalents were $13.0 million as of March 2026 after new funding.

Bottom Line

RenovoRx has shifted from research to early commercial sales, focusing on targeted cancer therapies. Its future depends on expanding device adoption and clinical trial outcomes.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

Shaun R. Bagai

Website

www.renovorx.com

Headquarters

Mountain View, CA 94022, US

RNXT Financials

Key Financial Metrics (TTM)

Gross Margin

78.71%

Operating Margin

-864.34%

Net Income Margin

-823.98%

Return on Equity

-138.61%

Return on Capital

-222.04%

Return on Assets

-87.86%

Earnings Yield

-38.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$38.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.05M

Volume

112.22K

Avg. Volume

278.07K

Financials (TTM)

Gross Profit

$1.17M

Operating Income

-$12.87M

EBITDA

-$12.27M

Operating Cash Flow

-$11.30M

Capital Expenditure

$0.00

Free Cash Flow

-$11.30M

Cash & ST Invst.

$12.36M

Total Debt

$186.00K

RenovoRx Performance Analysis

RenovoRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 43,000N/A
20252025-12-31USD 1,123,0002511.6%
RenovoRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30114.2%
Q32025-09-30-37.0%
Q42025-12-31-10.5%
Q12026-03-31136.6%
RenovoRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.0954.3%
20232023-12-31USD -0.99-9.0%
20242024-12-31USD -0.40-60.2%
20252025-12-31USD -0.32-20.1%
RenovoRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-2.7%
Q32025-09-30-1.0%
Q42025-12-31-4.6%
Q12026-03-31-10.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$563.00K

+185.8%

Gross Profit

$479.00K

+365.0%

Gross Margin

85.08%

N/A

Market Cap

$38.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.29M

N/A

Employees

17

N/A

Net Income

-$3.52M

-45.5%

EBITDA

-$3.52M

-45.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.36M

-15.2%

Total Debt

$186.00K

-34.3%

Accounts Receivable

$280.00K

+15.7%

Inventory

$379.00K

N/A

Long Term Debt

$78.00K

-58.1%

Short Term Debt

$108.00K

+11.3%

Return on Assets

-87.86%

N/A

Return on Invested Capital

-1.07%

N/A

Free Cash Flow

-$3.71M

-9.6%

Operating Cash Flow

-$3.71M

-9.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LTRNLantern Pharma Inc.
$2.87-1.37%
ELUTElutia Inc
$0.95+0.00%
ANVSAnnovis Bio, Inc.
$1.74+0.00%
TVRDTvardi Therapeutics, Inc.
$3.20+3.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
NFLXNetflix
$68.95-0.07%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About RNXT

What is the current price of RenovoRx?

RenovoRx is trading at $0.87 per share.

What is the 52-week range for RenovoRx?

Over the past 52 weeks, RenovoRx has traded between $0.70 and $1.45.

How much debt does RenovoRx have?

As of the most recent reporting period, RenovoRx reported total debt of $186.00K.

How much cash does RenovoRx have on hand?

RenovoRx reported $12.36M in cash and cash equivalents in its most recent financial results.

What is RenovoRx’s dividend yield?

RenovoRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services